(Q45922591)

English

V1/V2 Vasopressin receptor antagonism potentiates the renoprotection of renin-angiotensin system inhibition in rats with renal mass reduction.

scientific article published on 22 July 2009

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

17 December 2017

http://europepmc.org/abstract/MED/19625993

V1/V2 Vasopressin receptor antagonism potentiates the renoprotection of renin-angiotensin system inhibition in rats with renal mass reduction. (English)

1 reference

Europe PubMed Central

PubMed publication ID

17 December 2017

http://europepmc.org/abstract/MED/19625993

0 references

Giuseppe Remuzzi

7

1 reference

Europe PubMed Central

PubMed publication ID

17 December 2017

http://europepmc.org/abstract/MED/19625993

author name string

Norberto Perico

1

1 reference

Europe PubMed Central

PubMed publication ID

17 December 2017

http://europepmc.org/abstract/MED/19625993

Carla Zoja

2

1 reference

Europe PubMed Central

PubMed publication ID

17 December 2017

http://europepmc.org/abstract/MED/19625993

Daniela Corna

3

1 reference

Europe PubMed Central

PubMed publication ID

17 December 2017

http://europepmc.org/abstract/MED/19625993

Daniela Rottoli

4

1 reference

Europe PubMed Central

PubMed publication ID

17 December 2017

http://europepmc.org/abstract/MED/19625993

Flavio Gaspari

5

1 reference

Europe PubMed Central

PubMed publication ID

17 December 2017

http://europepmc.org/abstract/MED/19625993

Lloyd Haskell

6

1 reference

Europe PubMed Central

PubMed publication ID

17 December 2017

http://europepmc.org/abstract/MED/19625993

language of work or name

0 references

publication date

22 July 2009

1 reference

Europe PubMed Central

PubMed publication ID

17 December 2017

http://europepmc.org/abstract/MED/19625993

Kidney International

1 reference

Europe PubMed Central

PubMed publication ID

17 December 2017

http://europepmc.org/abstract/MED/19625993

76

1 reference

Europe PubMed Central

PubMed publication ID

17 December 2017

http://europepmc.org/abstract/MED/19625993

9

1 reference

Europe PubMed Central

PubMed publication ID

17 December 2017

http://europepmc.org/abstract/MED/19625993

960-967

1 reference

Europe PubMed Central

PubMed publication ID

17 December 2017

http://europepmc.org/abstract/MED/19625993

Pathophysiology of Progressive Nephropathies

1 reference

https://api.crossref.org/works/10.1038%2FKI.2009.267

7 January 2021

based on heuristic

inferred from DOI database lookup

Chronic renal diseases: renoprotective benefits of renin-angiotensin system inhibition

1 reference

https://api.crossref.org/works/10.1038%2FKI.2009.267

7 January 2021

based on heuristic

inferred from DOI database lookup

Cellular responses to protein overload: key event in renal disease progression

1 reference

https://api.crossref.org/works/10.1038%2FKI.2009.267

7 January 2021

based on heuristic

inferred from DOI database lookup

Is glomerulosclerosis a consequence of altered glomerular permeability to macromolecules?

1 reference

https://api.crossref.org/works/10.1038%2FKI.2009.267

7 January 2021

based on heuristic

inferred from DOI database lookup

Prevention of progression and remission/regression strategies for chronic renal diseases: can we do better now than five years ago?

1 reference

https://api.crossref.org/works/10.1038%2FKI.2009.267

7 January 2021

based on heuristic

inferred from DOI database lookup

Vasoactive agents affect growth and protein synthesis of cultured rat mesangial cells

1 reference

https://api.crossref.org/works/10.1038%2FKI.2009.267

7 January 2021

based on heuristic

inferred from DOI database lookup

Molecular pharmacology of human vasopressin receptors

1 reference

https://api.crossref.org/works/10.1038%2FKI.2009.267

7 January 2021

based on heuristic

inferred from DOI database lookup

Effects of tolvaptan, a vasopressin antagonist, in patients hospitalized with worsening heart failure: a randomized controlled trial

1 reference

https://api.crossref.org/works/10.1038%2FKI.2009.267

7 January 2021

based on heuristic

inferred from DOI database lookup

The basic and clinical pharmacology of nonpeptide vasopressin receptor antagonists

1 reference

https://api.crossref.org/works/10.1038%2FKI.2009.267

7 January 2021

based on heuristic

inferred from DOI database lookup

OPC-21268, an Orally Effective, Nonpeptide Vasopressin V1 Receptor Antagonist

1 reference

https://api.crossref.org/works/10.1038%2FKI.2009.267

7 January 2021

based on heuristic

inferred from DOI database lookup

Next-generation spirobenzazepines: identification of RWJ-676070 as a balanced vasopressin V1a/V2 receptor antagonist for human clinical studies

1 reference

https://api.crossref.org/works/10.1038%2FKI.2009.267

7 January 2021

based on heuristic

inferred from DOI database lookup

Pharmacological characterization of RWJ-676070, a dual vasopressin V(1A)/V(2) receptor antagonist

1 reference

https://api.crossref.org/works/10.1038%2FKI.2009.267

7 January 2021

based on heuristic

inferred from DOI database lookup

Role of heparin as a protective agent following reduction of renal mass

1 reference

https://api.crossref.org/works/10.1038%2FKI.2009.267

7 January 2021

based on heuristic

inferred from DOI database lookup

Renoprotection by nitric oxide donor and lisinopril in the remnant kidney model.

1 reference

https://api.crossref.org/works/10.1038%2FKI.2009.267

7 January 2021

based on heuristic

inferred from DOI database lookup

Effects of treatment with angiotensin-converting enzyme inhibitor (ACEI) or angiotensin II receptor antagonist (AIIRA) on renal function and glomerular injury in subtotal nephrectomized rats

1 reference

https://api.crossref.org/works/10.1038%2FKI.2009.267

7 January 2021

based on heuristic

inferred from DOI database lookup

Evidence for the involvement of vasopressin in the pathophysiology of adriamycin-induced nephropathy in rats

1 reference

https://api.crossref.org/works/10.1038%2FKI.2009.267

7 January 2021

based on heuristic

inferred from DOI database lookup

Effects of vasopressin V1 and V2 receptor antagonists on progressive renal failure in rats

1 reference

https://api.crossref.org/works/10.1038%2FKI.2009.267

7 January 2021

based on heuristic

inferred from DOI database lookup

Effect of a nonpeptide vasopressin V1 antagonist (OPC-21268) on experimental accelerated focal glomerulosclerosis

1 reference

https://api.crossref.org/works/10.1038%2FKI.2009.267

7 January 2021

based on heuristic

inferred from DOI database lookup

Diabetes-induced albuminuria: role of antidiuretic hormone as revealed by chronic V2 receptor antagonism in rats

1 reference

https://api.crossref.org/works/10.1038%2FKI.2009.267

7 January 2021

based on heuristic

inferred from DOI database lookup

Effects of Novel, Nonpeptide Vasopressin Antagonists on Progressive Nephrosclerosis in Rats

1 reference

https://api.crossref.org/works/10.1038%2FKI.2009.267

7 January 2021

based on heuristic

inferred from DOI database lookup

Early, but not late therapy with a vasopressin V1a-antagonist ameliorates the development of renal damage after 5/6 nephrectomy

1 reference

https://api.crossref.org/works/10.1038%2FKI.2009.267

7 January 2021

based on heuristic

inferred from DOI database lookup

Contribution of vasopressin to progression of chronic renal failure: study in Brattleboro rats

1 reference

https://api.crossref.org/works/10.1038%2FKI.2009.267

7 January 2021

based on heuristic

inferred from DOI database lookup

Angiotensin II and vasopressin stimulate calcium-activated chloride conductance in rat mesangial cells

1 reference

https://api.crossref.org/works/10.1038%2FKI.2009.267

7 January 2021

based on heuristic

inferred from DOI database lookup

Direct and indirect cost of urea excretion.

1 reference

https://api.crossref.org/works/10.1038%2FKI.2009.267

7 January 2021

based on heuristic

inferred from DOI database lookup

The effect of AVP-V2 receptor stimulation on local GFR in the rat kidney

1 reference

https://api.crossref.org/works/10.1038%2FKI.2009.267

7 January 2021

based on heuristic

inferred from DOI database lookup

Present and future drug treatments for chronic kidney diseases: evolving targets in renoprotection

1 reference

https://api.crossref.org/works/10.1038%2FKI.2009.267

7 January 2021

based on heuristic

inferred from DOI database lookup

Chronic exposure to vasopressin upregulates ENaC and sodium transport in the rat renal collecting duct and lung

1 reference

https://api.crossref.org/works/10.1038%2FKI.2009.267

7 January 2021

based on heuristic

inferred from DOI database lookup

Renoprotective benefits of RAS inhibition: from ACEI to angiotensin II antagonists

1 reference

https://api.crossref.org/works/10.1038%2FKI.2009.267

7 January 2021

based on heuristic

inferred from DOI database lookup

Progression, remission, regression of chronic renal diseases

1 reference

https://api.crossref.org/works/10.1038%2FKI.2009.267

7 January 2021

based on heuristic

inferred from DOI database lookup

Therapeutic advantage of converting enzyme inhibitors in arresting progressive renal disease associated with systemic hypertension in the rat

1 reference

https://api.crossref.org/works/10.1038%2FKI.2009.267

7 January 2021

based on heuristic

inferred from DOI database lookup

Prevention of diabetic glomerulopathy by pharmacological amelioration of glomerular capillary hypertension

1 reference

https://api.crossref.org/works/10.1038%2FKI.2009.267

7 January 2021

based on heuristic

inferred from DOI database lookup

The renoprotective properties of angiotensin-converting enzyme inhibitors in a chronic model of membranous nephropathy are solely due to the inhibition of angiotensin II: evidence based on comparative studies with a receptor antagonist

1 reference

https://api.crossref.org/works/10.1038%2FKI.2009.267

7 January 2021

based on heuristic

inferred from DOI database lookup

Effect of combining ACE inhibitor and statin in severe experimental nephropathy

1 reference

https://api.crossref.org/works/10.1038%2FKI.2009.267

7 January 2021

based on heuristic

inferred from DOI database lookup

Addition of AT1 blocker fails to overcome resistance to ACE inhibition in adriamycin nephrosis

1 reference

https://api.crossref.org/works/10.1038%2FKI.2009.267

7 January 2021

based on heuristic

inferred from DOI database lookup

Combined blockade of the renin-angiotensin system with angiotensin-converting enzyme inhibitors and angiotensin II type 1 receptor antagonists

1 reference

https://api.crossref.org/works/10.1038%2FKI.2009.267

7 January 2021

based on heuristic

inferred from DOI database lookup

Inhibition of renin secretion by angiotensin. II.

1 reference

https://api.crossref.org/works/10.1038%2FKI.2009.267

7 January 2021

based on heuristic

inferred from DOI database lookup

Vasopressin regulates the renin-angiotensin-aldosterone system via V1a receptors in macula densa cells

1 reference

https://api.crossref.org/works/10.1038%2FKI.2009.267

7 January 2021

based on heuristic

inferred from DOI database lookup

Minimization of variation in the response to different proteins of the Coomassie blue G dye-binding assay for protein

1 reference

https://api.crossref.org/works/10.1038%2FKI.2009.267

7 January 2021

based on heuristic

inferred from DOI database lookup

Identifiers

10.1038/KI.2009.267

1 reference

Europe PubMed Central

PubMed publication ID

17 December 2017

http://europepmc.org/abstract/MED/19625993

Dimensions Publication ID

0 references

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

17 December 2017

http://europepmc.org/abstract/MED/19625993

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q45922591&oldid=2207459526"